<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Barrett's <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">columnar-lined oesophagus</z:e> is the precursor lesion for oesophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>The overall rate of progression to <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> is 0.59% per annum </plain></SENT>
<SENT sid="2" pm="."><plain>A large prospective multicentre trial is recruiting to assess the role of aspirin as a chemoprotective agent in prevention of development of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> as well as cardiovascular protection in patients with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>This retrospective analysis of the large UK National <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's Oesophagus</z:e> Registry database seeks to analyse this question from within its large natural history study cohort </plain></SENT>
<SENT sid="4" pm="."><plain>Multicentre UK retrospective cohort compared patients known to have been taking aspirin with those who did not take aspirin during the course of surveillance for <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">columnar-lined oesophagus</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>End point was development of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or oesophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>Analysis was undertaken using Cox's proportional hazard ratio </plain></SENT>
<SENT sid="7" pm="."><plain>Total follow-up was 3683 patient-years </plain></SENT>
<SENT sid="8" pm="."><plain>Eighty-six patients were taking aspirin, 650 were not taking aspirin (reference group) </plain></SENT>
<SENT sid="9" pm="."><plain>Numbers of patients developing <z:hpo ids='HP_0000001'>all</z:hpo> grades of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> were: 13 aspirin (15.1%) and 97 no aspirin (14.9%) (hazard ratio 0.723, 95% confidence interval 0.410-1.310, P = 0.294), high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>: five aspirin (5.8%) and 25 no aspirin (3.8%) (hazard ratio 0.898, 95% confidence interval 0.340-2.368, P = 0.827) and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>: four aspirin (4.7%) and 16 no aspirin (2.5%) (hazard ratio 1.092, 95% confidence interval 0.358-3.335, P = 0.877) </plain></SENT>
<SENT sid="10" pm="."><plain>No significant difference was observed in hazard of developing <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> between patients taking aspirin and those not taking aspirin during the course of follow-up of surveillance for <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">columnar-lined oesophagus</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>In conclusion, no difference in risk of development of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> was observed between patients taking aspirin and those not taking aspirin in this large cohort </plain></SENT>
</text></document>